Ikarian Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Ikarian Capital’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-122,600	Closed	-$2.27M	–	110
2022 Q3	$2.27M	Buy	+122,600	New	+$1.92M	0.45%	56
2022 Q1	–	Sell	-29,800	Closed	-$291K	–	214
2021 Q4	$291K	Hold	29,800	–	–	0.04%	150
2021 Q3	$1.01M	Buy	+29,800	New	+$951K	0.07%	156
2021 Q1	–	Sell	-140,000	Closed	-$7.99M	–	336
2020 Q4	$7.99M	Hold	140,000	–	–	0.35%	68
2020 Q3	$7.18M	Buy	+140,000	New	+$6.86M	0.52%	47
2020 Q1	–	Sell	-100,000	Closed	-$6.22M	–	183
2019 Q4	$6.22M	Buy	+100,000	New	+$4.75M	1.01%	32

Other funds holding DCPH

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's DCPH Position: Q3 2023 in Review

Ikarian Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2023, closing a stake of 174,510 shares — an estimated $2.46M sold.

Ikarian Capital first reported a position in DCPH in Q3 2022 and held it in 4 quarters. The position peaked at $9.11M in Q3 2022. 157 funds tracked by Wall St. Rank hold DCPH as of Q3 2023.

Ikarian Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 174,510 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $2.46M.
Ikarian Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Ikarian Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $9.11M in Q3 2022.
157 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.